Skip to main navigation

Overview
Corporate
News & Events
Stock Information
Financial Information
- SEC Filings
- Quarterly Results
IR Resources

News & Events

News Releases

News Releases

All
2024
2023
2022
2021
2020
2019

2021.03.29

Adagene Announces Clinical Advancement for ADG116

2021.03.16

Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program

2021.02.11

Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option

2021.02.09

Adagene Inc. Announces Pricing of Initial Public Offering

2021.02.01

Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Next page
Last page

Displaying 21 - 25 of 26

Shareholder Tools

© 2024 Adagene Inc.

Footer Bottom

Home
Privacy
Terms of Use
Contact
Site Credits
LinkedIn